-
1
-
-
5344263788
-
The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients
-
Ludwig H, Van Belle S, Barrett-Lee P et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-2306.
-
(2004)
Eur J Cancer
, vol.40
, pp. 2293-2306
-
-
Ludwig, H.1
van Belle, S.2
Barrett-Lee, P.3
-
2
-
-
0033530262
-
Chemotherapy-induced anemia in adults: Incidence and treatment
-
Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 1999;91:1616-1634.
-
(1999)
J Natl Cancer Inst
, vol.91
, pp. 1616-1634
-
-
Groopman, J.E.1
Itri, L.M.2
-
3
-
-
0002929285
-
Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy
-
Henry DH, Brooks BJ Jr, Case DC Jr et al. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. Cancer J Sci Am 1995;1:252-260.
-
(1995)
Cancer J Sci Am
, vol.1
, pp. 252-260
-
-
Henry, D.H.1
Brooks Jr., B.J.2
Case Jr., D.C.3
-
4
-
-
0037151364
-
Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy
-
Vansteenkiste J, Pirker R, Massuti B et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-1220.
-
(2002)
J Natl Cancer Inst
, vol.94
, pp. 1211-1220
-
-
Vansteenkiste, J.1
Pirker, R.2
Massuti, B.3
-
5
-
-
0031044609
-
Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice
-
Glaspy J, Bukowski R, Steinberg D et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997; 15:1218-1234.
-
(1997)
J Clin Oncol
, vol.15
, pp. 1218-1234
-
-
Glaspy, J.1
Bukowski, R.2
Steinberg, D.3
-
6
-
-
0031785826
-
Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. Procrit Study Group
-
Demetri GD, Kris M, Wade J et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412-3425.
-
(1998)
J Clin Oncol
, vol.16
, pp. 3412-3425
-
-
Demetri, G.D.1
Kris, M.2
Wade, J.3
-
7
-
-
0035367087
-
Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebocontrolled trial
-
Littlewood TJ, Bajetta E, Nortier JW et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebocontrolled trial. J Clin Oncol 2001;19:2865-2874.
-
(2001)
J Clin Oncol
, vol.19
, pp. 2865-2874
-
-
Littlewood, T.J.1
Bajetta, E.2
Nortier, J.W.3
-
8
-
-
33744822764
-
Randomized comparison of every-2 -week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: The 200030125 Study Group Trial
-
Glaspy J, Vadhan-Raj S, Patel R et al. Randomized comparison of every-2 -week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: The 200030125 Study Group Trial. J Clin Oncol 2006;24:2290-2297.
-
(2006)
J Clin Oncol
, vol.24
, pp. 2290-2297
-
-
Glaspy, J.1
Vadhan-Raj, S.2
Patel, R.3
-
9
-
-
1542324739
-
Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks
-
Vadhan-Raj S, Mirtsching B, Charu V et al. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. J Support Oncol 2003;1:131-138.
-
(2003)
J Support Oncol
, vol.1
, pp. 131-138
-
-
Vadhan-Raj, S.1
Mirtsching, B.2
Charu, V.3
-
10
-
-
0035366382
-
Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing
-
Gabrilove JL, Cleeland CS, Livingston RB et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-2882.
-
(2001)
J Clin Oncol
, vol.19
, pp. 2875-2882
-
-
Gabrilove, J.L.1
Cleeland, C.S.2
Livingston, R.B.3
-
11
-
-
0042889128
-
Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy
-
Shasta D, George MJ, Harrison LB. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 2003;98:1072-1079.
-
(2003)
Cancer
, vol.98
, pp. 1072-1079
-
-
Shasta, D.1
George, M.J.2
Harrison, L.B.3
-
12
-
-
0142186283
-
Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomized, double-blind, placebo-controlled trial
-
Henke M, Laszig R, Rübe C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomized, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
-
(2003)
Lancet
, vol.362
, pp. 1255-1260
-
-
Henke, M.1
Laszig, R.2
Rübe, C.3
-
13
-
-
24944454286
-
Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study
-
Leyland-Jones B, Semiglazov V, Pawlicki M et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 2005;23:5960-5972.
-
(2005)
J Clin Oncol
, vol.23
, pp. 5960-5972
-
-
Leyland-Jones, B.1
Semiglazov, V.2
Pawlicki, M.3
-
14
-
-
34047221511
-
Randomized, double-blind, placebocontrolled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia
-
Wright JR, Ung YC, Julian JA et al. Randomized, double-blind, placebocontrolled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007;25:1027-1032.
-
(2007)
J Clin Oncol
, vol.25
, pp. 1027-1032
-
-
Wright, J.R.1
Ung, Y.C.2
Julian, J.A.3
-
15
-
-
38649128164
-
Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dl with erythropoietin vs above 10.0 g/dl without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer
-
Thomas G, Ali S, Hoebers FJ et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dl with erythropoietin vs above 10.0 g/dl without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 2008;108: 317-325.
-
(2008)
Gynecol Oncol
, vol.108
, pp. 317-325
-
-
Thomas, G.1
Ali, S.2
Hoebers, F.J.3
-
16
-
-
34250349918
-
Danish researchers post long-awaited Aranesp results-ever so discreetly
-
Goldberg P. Danish researchers post long-awaited Aranesp results-ever so discreetly. Cancer Lett 2007;33:1-6.
-
(2007)
Cancer Lett
, vol.33
, pp. 1-6
-
-
Goldberg, P.1
-
17
-
-
40549088086
-
Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): The Danish Head and Neck Cancer Group DAHANCA 10 rand [abstract]
-
Overgaard J, Hoff C, Sand Hansen H et al. Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): The Danish Head and Neck Cancer Group DAHANCA 10 rand [abstract]. Eur J Cancer 2007;5:7.
-
(2007)
Eur J Cancer
, vol.5
, pp. 7
-
-
Overgaard, J.1
Hoff, C.2
Sand, H.H.3
-
18
-
-
28444469283
-
Randomized, doubleblind, placebo-controlled trial of epoetin alfa (Procrit) in patients with rectal and gastric cancer undergoing chemo-radiotherapy (CT/RT) followed by surgery: Early termination of the trial due to increased incidence of thrombo-embolic events (TEE)
-
Vadhan-Raj S, Crane C, Bueso-Ramos CE et al. Randomized, doubleblind, placebo-controlled trial of epoetin alfa (Procrit) in patients with rectal and gastric cancer undergoing chemo-radiotherapy (CT/RT) followed by surgery: Early termination of the trial due to increased incidence of thrombo-embolic events (TEE). Blood 104:797a.
-
Blood
, vol.104
-
-
Vadhan-Raj, S.1
Crane, C.2
Bueso-Ramos, C.E.3
-
19
-
-
0041627742
-
Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies:A randomized, double-blind, placebo-controlled study
-
Hedenus M, Adriansson M, San Miguel J et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies:A randomized, double-blind, placebo-controlled study. Br J Haematol 2003; 122:394-403.
-
(2003)
Br J Haematol
, vol.122
, pp. 394-403
-
-
Hedenus, M.1
Adriansson, M.2
San, M.J.3
-
20
-
-
41949140285
-
Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled study
-
Smith RE, Aapro MS, Ludwig H et al. Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008;26:1040-1050.
-
(2008)
J Clin Oncol
, vol.26
, pp. 1040-1050
-
-
Smith, R.E.1
Aapro, M.S.2
Ludwig, H.3
-
21
-
-
40349103260
-
Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia
-
Bennett CL, Silver SM, Djulbegovic B et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299:914-924.
-
(2008)
JAMA
, vol.299
, pp. 914-924
-
-
Bennett, C.L.1
Silver, S.M.2
Djulbegovic, B.3
-
22
-
-
50349088773
-
Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer
-
Juneja V, Keegan P, Gootenberg JE et al. Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer. Clin Cancer Res 2008;14:3242-3247.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 3242-3247
-
-
Juneja, V.1
Keegan, P.2
Gootenberg, J.E.3
-
23
-
-
77951700065
-
-
U.S. Food and Drug Administration, March 2007 label. Available at, accessed March 11, 2009
-
U.S. Food and Drug Administration. Drugs at FDA: Pocrit and Epogen label. March 2007 label. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/103234s5122lbl.pdf, accessed March 11, 2009.
-
Drugs at FDA: Pocrit and Epogen Label
-
-
-
24
-
-
38049083499
-
-
Centers for Medicare & Medicaid Services, Washington, DC: Department of Health & Human Services, Available at, accessed November 17, 2010
-
Centers for Medicare & Medicaid Services. Decision Memo for Erythropoiesis Stimulating Agents (ESAs) for Non-Renal Disease Indications (CAG-00383N). Washington, DC: Department of Health & Human Services, 2007. Available at https://www.cms.gov/mcd/viewdecisionmemo.asp?id=203, accessed November 17, 2010.
-
(2007)
Decision Memo for Erythropoiesis Stimulating Agents (ESAs) for Non-Renal Disease Indications (CAG-00383N)
-
-
-
25
-
-
78650983148
-
-
U.S. Food and Drug Administration, November, label. Available at, accessed March 11, 2009
-
U.S. Food and Drug Administration. Drugs at FDA: Procrit and Epogen Label. November 2007 label. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/103234s5158lbl.pdf, accessed March 11, 2009.
-
(2007)
Drugs at FDA: Procrit and Epogen Label
-
-
-
26
-
-
77951700065
-
-
U.S. Food and Drug Administration, November 2007 label. Available at, accessed March 11, 2009
-
U.S. Food and Drug Administration. Drugs at FDA: Aranesp® (Darbepoetin Alfa) For Injection. November 2007 label. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/103951s5164lbl.pdf, accessed March 11, 2009.
-
Drugs at FDA: Aranesp® (Darbepoetin Alfa) for Injection
-
-
-
27
-
-
77957714130
-
Continued regulatory actions affecting the use of erythropoiesis-stimulating Agents
-
Hagerty K. Continued regulatory actions affecting the use of erythropoiesis-stimulating Agents. J Oncol Pract 2008;4:267-270.
-
(2008)
J Oncol Pract
, vol.4
, pp. 267-270
-
-
Hagerty, K.1
-
29
-
-
78549286047
-
American Society of Hematology/ American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer
-
Rizzo JD, Brouwers M, Hurley P et al. American Society of Hematology/ American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood; 2010;116:4045-4059.
-
(2010)
Blood
, vol.116
, pp. 4045-4059
-
-
Rizzo, J.D.1
Brouwers, M.2
Hurley, P.3
-
31
-
-
65349104834
-
Impact of limiting erythropoiesisstimulating agent use for chemotherapy induced anemia on the United States blood supply margin
-
Vekeman F, Bookhart BK, Duh MS et al. Impact of limiting erythropoiesisstimulating agent use for chemotherapy induced anemia on the United States blood supply margin. Transfusion 2009;49:895-902.
-
(2009)
Transfusion
, vol.49
, pp. 895-902
-
-
Vekeman, F.1
Bookhart, B.K.2
Duh, M.S.3
-
32
-
-
39049138428
-
Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies ((DOSE): A registry for characterizing anaemia management and outcomes in oncology patients
-
Larholt K, Pashos CL, Wang Q et al. Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies ((DOSE): A registry for characterizing anaemia management and outcomes in oncology patients. Clin Drug Investig 2008;28:159-167.
-
(2008)
Clin Drug Investig
, vol.28
, pp. 159-167
-
-
Larholt, K.1
Pashos, C.L.2
Wang, Q.3
-
33
-
-
78650994365
-
Changes in RBC supportive medications and transfusions in cancer patients undergoing chemotherapy before and after FDA and Medicare actions in 2007 [abstract 20595]
-
Nailm A, Glaspy J. Changes in RBC supportive medications and transfusions in cancer patients undergoing chemotherapy before and after FDA and Medicare actions in 2007 [abstract 20595]. J Clin Oncol 2008;26(15 suppl):732s.
-
(2008)
J Clin Oncol
, vol.26
, Issue.15 SUPPL
-
-
Nailm, A.1
Glaspy, J.2
-
35
-
-
31444447968
-
Patients previously transfused or treated with epoetin alfa at low baseline hemoglobin are at higher risk for subsequent transfusion: An integrated analysis of the Canadian experience
-
Quirt I, Kovacs M, Couture F et al. Patients previously transfused or treated with epoetin alfa at low baseline hemoglobin are at higher risk for subsequent transfusion: An integrated analysis of the Canadian experience. The Oncologist 2006;11:73-82.
-
(2006)
The Oncologist
, vol.11
, pp. 73-82
-
-
Quirt, I.1
Kovacs, M.2
Couture, F.3
-
36
-
-
54049148231
-
Treatment options for anemia, taking risks into consideration: Erythropoiesis-stimulating agents versus transfusions
-
Spano JP, Khayat D. Treatment options for anemia, taking risks into consideration: Erythropoiesis-stimulating agents versus transfusions. The Oncologist 2008;13(suppl 3):27-32.
-
(2008)
The Oncologist
, vol.13
, Issue.SUPPL. 3
, pp. 27-32
-
-
Spano, J.P.1
Khayat, D.2
-
37
-
-
12844275064
-
Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management
-
Couture F, Turner AR, Melosky B et al. Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management. The Oncologist 2005;10: 63-71.
-
(2005)
The Oncologist
, vol.10
, pp. 63-71
-
-
Couture, F.1
Turner, A.R.2
Melosky, B.3
-
38
-
-
78650982185
-
Impact of safety concerns of erythropoiesis-stimulating agents (ESAs) and regulatory changes on the use of ESAs and red blood cell (RBC) transfusions at a comprehensive cancer center [abstract 1300]
-
Vadhan-Raj S, Hawkins V, Zhou X et al. Impact of safety concerns of erythropoiesis-stimulating agents (ESAs) and regulatory changes on the use of ESAs and red blood cell (RBC) transfusions at a comprehensive cancer center [abstract 1300]. Blood 2008;112:470.
-
(2008)
Blood
, vol.112
, pp. 470
-
-
Vadhan-Raj, S.1
Hawkins, V.2
Zhou, X.3
-
39
-
-
78650985531
-
The impact of randomized trial results and altered regulatory policies on ESA use, transfusions and thrombosis: A longitudinal analysis over a 3-year period of resource utilization data from a large comprehensive program [abstract 6611]
-
Shapira I, Raftopoulos H, Gralla RJ et al. The impact of randomized trial results and altered regulatory policies on ESA use, transfusions and thrombosis: A longitudinal analysis over a 3-year period of resource utilization data from a large comprehensive program [abstract 6611]. J Clin Oncol 2009;27(15 suppl):350s.
-
(2009)
J Clin Oncol
, vol.27
, Issue.15 SUPPL
-
-
Shapira, I.1
Raftopoulos, H.2
Gralla, R.J.3
|